205 related articles for article (PubMed ID: 21190649)
1. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2010; 71 Suppl 2():20-6. PubMed ID: 21190649
[TBL] [Abstract][Full Text] [Related]
2. Treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
[TBL] [Abstract][Full Text] [Related]
3. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.
Patel MX; de Zoysa N; Bernadt M; David AS
J Clin Psychiatry; 2008 Oct; 69(10):1548-56. PubMed ID: 19192437
[TBL] [Abstract][Full Text] [Related]
4. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
Sajatovic M; Levin J; Ramirez LF; Hahn DY; Tatsuoka C; Bialko CS; Cassidy KA; Fuentes-Casiano E; Williams TD
J Clin Psychiatry; 2013 Dec; 74(12):1249-55. PubMed ID: 24434094
[TBL] [Abstract][Full Text] [Related]
5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
6. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
7. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.
Valenstein M; Copeland LA; Owen R; Blow FC; Visnic S
J Clin Psychiatry; 2001 Jul; 62(7):545-51. PubMed ID: 11488366
[TBL] [Abstract][Full Text] [Related]
8. Improving treatment adherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
[TBL] [Abstract][Full Text] [Related]
9. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
Byerly MJ; Nakonezny PA; Rush AJ
Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
[TBL] [Abstract][Full Text] [Related]
10. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
11. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness.
Valenstein M; Kavanagh J; Lee T; Reilly P; Dalack GW; Grabowski J; Smelson D; Ronis DL; Ganoczy D; Woltmann E; Metreger T; Wolschon P; Jensen A; Poddig B; Blow FC
Schizophr Bull; 2011 Jul; 37(4):727-36. PubMed ID: 19933540
[TBL] [Abstract][Full Text] [Related]
12. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
[TBL] [Abstract][Full Text] [Related]
13. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
Morrissette DA; Stahl SM
CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
[TBL] [Abstract][Full Text] [Related]
14. The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia.
Nakonezny PA; Byerly MJ; Pradhan A
Psychiatry Res; 2013 Jun; 208(1):9-14. PubMed ID: 23473653
[TBL] [Abstract][Full Text] [Related]
15. Long-term psychiatric patients' knowledge about their medication.
Tempier R
Psychiatr Serv; 1996 Dec; 47(12):1385-7. PubMed ID: 9117480
[TBL] [Abstract][Full Text] [Related]
16. [Depot antipsychotics in the year 2011].
Knegtering H; Oolders H; Ruijsink MA; van der Moolen AE
Tijdschr Psychiatr; 2011; 53(2):95-105. PubMed ID: 21319066
[TBL] [Abstract][Full Text] [Related]
17. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia.
Patterson TL; Lacro J; McKibbin CL; Moscona S; Hughs T; Jeste DV
J Clin Psychopharmacol; 2002 Feb; 22(1):11-9. PubMed ID: 11799337
[TBL] [Abstract][Full Text] [Related]
18. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial.
Priebe S; Bremner SA; Lauber C; Henderson C; Burns T
Health Technol Assess; 2016 Sep; 20(70):1-122. PubMed ID: 27682868
[TBL] [Abstract][Full Text] [Related]
19. Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.
Noordraven EL; Audier CH; Staring AB; Wierdsma AI; Blanken P; van der Hoorn BE; Roijen LH; Mulder CL
BMC Psychiatry; 2014 Dec; 14():343. PubMed ID: 25438877
[TBL] [Abstract][Full Text] [Related]
20. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
Patel MX; De Zoysa N; Bernadt M; David A
J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
